Cargando…
Dynorphin‐based “release on demand” gene therapy for drug‐resistant temporal lobe epilepsy
Focal epilepsy represents one of the most common chronic CNS diseases. The high incidence of drug resistance, devastating comorbidities, and insufficient responsiveness to surgery pose unmet medical challenges. In the quest of novel, disease‐modifying treatment strategies of neuropeptides represent...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783645/ https://www.ncbi.nlm.nih.gov/pubmed/31486590 http://dx.doi.org/10.15252/emmm.201809963 |